Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 287, Issue 2 50-2, 2004, Pages

  Holst, Jens Juul ^a   Gromada, Jesper ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Lilly Research Laboratories   (Germany)

Author keywords

Diabetes; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HORMONE; INCRETIN; INSULIN; UNCLASSIFIED DRUG;

GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; NEUROSECRETORY SYSTEMS; PEPTIDE FRAGMENTS; PEPTIDE HORMONES; PROTEIN PRECURSORS;

EID: 3242730474     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00545.2003     Document Type: Short Survey

References (86)

1. Almind K, Ambye L, Urhammer SA, Hansen T, Echwald SM, Holst JJ, Gromada J, Thorens B, and Pedersen O. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41: 1194-1198, 1998.
2. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, and Nielsen OV. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 21: 151-166, 1988.
3. Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab 11: 375-378, 2000.
4. Buteau J, Roduit R, Susini S, and Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42: 856-864, 1999.
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, and Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110, 2003.
6. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, and Bloom SR. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88: 4696-4701, 2003.
7. Creutzfeldt W. Entero-insular axis and diabetes mellitus. Horm Metab Res Suppl 26: 13-18, 1992.
8. Deckert T. Stimulation of insulin secretion by glucagon and secretin. Acta Endocrinol (Copenh) 57: 578-584, 1968.
9. Ding WG and Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 46: 615-621, 1997.
10. Ding WG, Renstrom E, Rorsman P, Buschard K, and Gromada J. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46: 792-800, 1997.
11. Dupre J, Ross SA, Watson D, and Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37: 826-828, 1973.
12. Ebert R and Creutzfeldt W. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology 111: 1601-1606, 1982.
13. Ebert R, Unger H, and Creutzfeldt W. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 24: 449-454, 1983.
14. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, and Bloom SR. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48: 86-93, 1999.
15. Egan JM, Bulotta A, Hui H, and Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 19: 115-123, 2003.
16. Ehlers MRW, Roderick EH, Schneider RL, and Kipnes MS. Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes (Abstract). Diabetes 51, Suppl 2: A579, 2002.
17. Ehses JA, Lee SS, Pederson RA, and McIntosh CH. A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in the GIP stimulated insulin secretion. J Biol Chem 276: 23667-23673, 2003.
18. Ehses JA, Pelech SL, Pederson RA, and McIntosh CH. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277: 37088-37097, 2002.
19. Elahi D, McAloon Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, and Andersen DK. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51: 63-74, 1994.
20. Fahrenkrug J, Schaffalitzky de Muckadell OB, and Kuhl C. Effect of secretin on basal- and glucose-stimulated insulin secretion in man. Diabetologia 14: 229-234, 1978.
21. Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, and Perfetti R. GLP-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003.
22. Fehmann HC, Goke R, and Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16: 390-410, 1995.
23. Fehmann HC and Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130: 159-166, 1992.
24. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, and Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26: 2370-2377, 2003.
25. Flamez D, Van Breusegem A, Scrocchi LA, Quartier E, Pipeleers D, Drucker DJ, and Schuit F. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes 47: 646-652, 1998.
26. Gault VA, O'Harte FP, Harriott P, and Flatt PR. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290: 1420-1426, 2002.
27. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, and Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47: 57-65, 1998.
28. Gromada J, Dissing S, Bokvist K, Renstrom E, Frokjaer-Jensen J, Wulff BS, and Rorsman P. Glucagon-like peptide I increases cytoplasmic calcium in insulin- secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes 44: 767-774, 1995.
29. Gromada J, Holst JJ, and Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch 435: 583-594, 1998.
30. Gutniak MK, Juntti-Berggren L, Hellstrom PM, Guenifi A, Holst JJ, and Efendic S. Glucagon-like peptide 1 enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19: 857-863, 1996.
31. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 24: 359-365, 1983.
32. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18: 430-441, 2002.
33. Holst JJ, Gromada J, and Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40: 984-986, 1997.
34. Holz GG. Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53: 5-13, 2004.
35. Holz GG, Kuhtreiber WM, and Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361: 362-365, 1993.
36. Kjems LL, Holst JJ, Volund A, and Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52: 380-386, 2003.
37. Kolligs F, Fehmann HC, Goke R, and Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19, 1995.
38. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 9: 122-134, 1988.
39. Kreymann B, Williams G, Ghatei MA, and Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304, 1987.
40. Kubota A, Yamada Y, Hayami T, Yasuda K, Someya Y, Ihara Y, Kagimoto S, Watanabe R, Taminato T, Tsuda K, and Seino Y. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 45: 1701-1705, 1996.
41. Lauritsen KB, Holst JJ, and Moody AJ. Depression of insulin release by anti-GIP serum after oral glucose in rats. Scand J Gastroenterol 16: 417-420, 1981.
42. Lauritsen KB, Moody AJ, Christensen KC, and Lindkaer JS. Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man. Scand J Gastroenterol 15: 833-840, 1980.
43. Lewis JT, Dayanandan B, Habener JF, and Kieffer TJ. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology 141: 3710-3716, 2000.
44. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, and Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471-478, 2003.
45. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, and Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50: 1004-1011, 2001.
46. Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, McIntosh CH, and Pederson RA. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J 17: 91-93, 2003.
47. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, and Drucker DJ. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55: 167-194, 2003.
48. McIntyre N, Holdsworth CD, and Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 25: 1317-1324, 1965.
49. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, and Nauck MA. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46: 798-801, 2003.
50. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, and Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50: 2497-2504, 2001.
51. Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, and Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26: 2835-2841, 2003.
52. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, and Seino Y. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96: 14843-14847, 1999.
53. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, and Habener JF. Preproglucagon gene expression in pancreas and intestine diversities at the level of post-translational processing. J Biol Chem 261: 11880-11889, 1986.
54. Mortensen K, Christensen LL, Holst JJ, and Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114: 189-196, 2003.
55. Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, and Creutzfeldt W. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 69: 654-662, 1989.
56. Nauck M, Stockmann F, Ebert R, and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52, 1986.
57. Nauck MA, Bartels E, Orskov C, Ebert R, and Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917, 1993.
58. Nauck MA, Busing M, Orskov C, Siegel EG, Talartschik J, Baartz A, Baartz T, Hopt UT, Becker HD, and Creutzfeldt W. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol 30: 39-45, 1993.
59. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307, 1993.
60. Nauck MA, Holst JJ, and Willms B. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 29: 411-416, 1997.
61. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, and Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498, 1986.
62. Niijima A. Neural mechanisms in the control of blood glucose concentration. J Nutr 119: 833-840, 1989.
63. Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KG, Holst JJ, and Schmitz O. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42: 1314-1323, 1999.
64. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, and Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119: 1467-1475, 1986.
65. Orskov C, Holst JJ, and Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123: 2009-2013, 1988.
66. Perfetti R, Zhou J, Doyle ME, and Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141: 4600-4605, 2000.
67. Preitner F, Burcelin R, Ibberson M, Hansotia T, Drucker D, and Thorens B. Disruption of both GLP-1 and GIP signalling pathways in the mouse leads to glucose intolerance (Abstract). Diabetes 51, Suppl 2: A66. 2002.
68. Rachman J, Barrow BA, Levy JC, and Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211, 1997.
69. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, and Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258, 1996.
70. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, and Egan JM. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49: 741-748, 2000.
71. Takeda J, Seino Y, Tanaka K, Fukumoto H, Kayano T, Takahashi H, Mitani T, Kurono M, Suzuki T, and Tobe T. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci USA 84: 7005-7008, 1987.
72. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, and Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86: 3717-3723, 2001.
73. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, and Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15: 1559-1570, 2001.
74. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, and Wolfe MM. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98: 2440-2445, 1996.
75. Tsuboi T, da Silva Xavier G, Holz GG, Jouaville LS, Thomas AP, and Rutter GA. Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem J 369: 287-299, 2003.
76. Unger RH and Eisentraut AM. Entero-insular axis. Arch Intern Med 123: 261-265, 1969.
77. Vaag AA, Holst JJ, Volund A, and Beck-Nielsen HB. Gut incretin hormones in identical twins discordant for non-insulin- dependent diabetes mellitus (NIDDM)-evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135: 425-432, 1996.
78. Vilsboll T, Agerso H, Krarup T, and Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88: 220-224, 2003.
79. Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, and Holst JJ. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88: 4897-4903, 2003.
80. Vilsboll T, Krarup T, Madsbad S, and Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45: 1111-1119, 2002.
81. Vilsboll T, Krarup T, Madsbad S, and Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114: 115-121, 2003.
82. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, and Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95: 417-421, 1995.
83. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, and Pederson RA. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 136: 4629-4639, 1995.
84. Xu G, Stoffers DA, Habener JF, and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276, 1999.
85. Zander M, Madsbad S, Madsen JL, and Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830, 2002.
86. Zhou J, Wang X, Pineyro MA, and Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancrteatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48: 2358-2366, 1990.